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Aim: This study evaluated the use of polymerase chain reaction for cryptococcal meningitis
diagnosis  in clinical samples.
Materials  and methods: The sensitivity and speciﬁcity of the methodology were  evaluated
using  eight Cryptococcus neoformans/C. gattii species complex reference strains and 165 cere-
brospinal ﬂuid samples from patients with neurological diseases divided into two groups:
96  patients with cryptococcal meningitis and AIDS; and 69 patients with other neurological
opportunistic  diseases (CRL/AIDS). Two primer sets were tested (CN4–CN5 and the multi-
plex  CNa70S–CNa70A/CNb49S–CNb-49A that amplify a speciﬁc product for C. neoformans
and  another for C. gattii).
Results:  CN4–CN5 primer set was positive in all Cryptococcus standard strains and in 94.8% in
DNA samples from cryptococcal meningitis and AIDS group. With the multiplex, no 448-bp
product  of C. gattii was observed in the clinical samples of either group. The 695 bp products
of  C. neoformans were observed only in 64.6% of the cryptococcal meningitis and AIDS group.
This  primer set was negative for two standard strains. The speciﬁcity based on the negative
samples  from the CTL/AIDS group was 98.5% in both primer sets.
Conclusions:  These data suggest that the CN4/CN5 primer set was highly sensitive for theidentiﬁcation  of C. neoformans/C. gattii species complex in cerebrospinal ﬂuid samples frompatients  with clinical susp
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ryptococcal meningitis is one of the most serious systemic
ycoses, mainly affecting immunocompromised patients
nd  causing high morbidity and mortality. The course of
nfection  is often a life-threatening disease that is typically
bserved in later stages of acquired immunodeﬁciency syn-
rome  (AIDS).1–4
Cryptococcal meningitis affects approximately one mil-
ion  persons in the world each year and results in more
han  400,000 deaths within three months after the onset
f  the disease.5 Latin America, as a global region, has the
hird  highest incidence of the disease, with around 54,400
ases  annually.6 Fortunately, in recent years, AIDS-associated
ryptococcal meningitis has decreased dramatically in Brazil,
hich  is a middle-income country with universal access
o  antiretroviral therapy.4,7 However, until today, cryptococ-
al  meningitis remains a common complication in Brazil
nd  other Latin American countries as it represents the pri-
ary  cause of opportunistic meningitis and the second-most
requent neurologic opportunistic infection in HIV-infected
atients.6,7
Patients with cryptococcal meningitis usually present
evere neurological manifestations, particularly secondary to
ntracranial hypertension.7–9 A rapid laboratorial diagnosis is
xtremely important to identify Cryptococcus species.10 Rou-
inely,  microscopic examination, cryptococcal polysaccharide
ntigen, and culture of cerebrospinal ﬂuid (CSF) samples lead
o  the diagnosis.
Several studies have demonstrated the use of molecular
ethods for determining the genetic characteristics of Cryp-
ococcus  species.11–15 Nevertheless, there is scarce information
bout the use of molecular diagnosis in clinical samples.
olecular methods such as polymerase chain reaction (PCR)
otentially  identify the fungus and the genotype of the
train.
Considering that no method is entirely effective in deter-
ining  the presence of this pathogen, it is helpful to diagnose
n  the basis of results obtained from different methodolo-
ies to rule out false-negative or false-positive results. Hence,
olecular  methods such as PCR have proven to be useful for
his  purpose, since they can provide a deﬁnitive diagnosis as
ell as evaluation of speciﬁc treatment.
The aim of this study is to evaluate the use of PCR for
olecular diagnosis of cryptococcal meningitis.
aterials  and  methods
he sensitivity and speciﬁcity of the methodology were eval-
ated  using Cryptococcus reference strains in the ﬁrst part and
SF  samples from patients with neurological diseases in the
econd  part of the study.
atients  and  clinical  sampleshe assays were  evaluated analyzing 165 CSF samples
ith  commonly used, well-known laboratory and clini-
al  diagnoses. The clinical samples were  divided into two 1 5;1  9(1):62–67  63
groups.  Group cryptococcal meningitis and AIDS (CM/AIDS)
consisted of 96 CSF samples from patients with CM/AIDS.
Cases of cryptococcal meningitis were  conﬁrmed using
positive microscopic examination by India ink and latex
agglutination of CSF samples.16 All patients were  admitted
to  the Instituto de Infectologia Emilio Ribas, Sao Paulo, SP,
Brazil.  The CRL/AIDS group (control) consisted of 69 CSF
samples  from patients with conﬁrmed diagnosis (by clinical,
radiological and laboratory features) of other neurological
opportunistic infections including cerebral toxoplasmosis,
progressive multifocal leukoencephalopathy, HIV-associated
neurocognitive disorders, tuberculous meningitis, and
neurosyphilis.
Ethical  considerations
All patients provided written informed consent. The insti-
tutional  review board of both Instituto Adolfo Lutz and
Instituto de Infectologia Emilio Ribas committees approved
this  study.
Laboratory  diagnosis
At the Instituto de Infectologia Emilio Ribas the CSF samples
were  collected in aseptic conditions, immediately transferred
to  sterile tubes, sent to laboratory and processed. Each sample
was  split in two tubes. One of them was  used for micro-
scopic examination by India ink and latex agglutination.
The other was  sent to the Instituto Adolfo Lutz for molec-
ular  diagnosis. Microscopic examinations by India ink was
conducted  as previously described.17,18 CSF samples were  cen-
trifuged  at 3000 × g for 10 min. One drop of the pellet was
used  for microscopic observation after India ink preparation.
The  polysaccharide capsule antigen was detected in CSF sam-
ples  using a latex agglutination Kit (Cryptococcus Antigen Latex
Agglutination  Test–Immy) according to the manufacturer’s
instructions.
Yeast  preparation
The assays were  also determined using DNA extracted from
standard  strains representing each molecular type including:
WM  148 (serotype A, VNI), WM 626 (serotype A, VNII), WM
628  (serotype AD, VNIII), WM 629 (serotype D,  VNIV), WM 179
(serotype  B, VGI), WM 178 (serotype B, VGII), WM 175 (serotype
B,  VGIII), and WM 779 (serotype C, VGIV).12 The strains were
prepared as previously described.12 Brieﬂy, each isolate was
plated  on Sabouraud dextrose agar and incubated at 30 ◦C for
48  h. The yeast cells were transferred to a microcentrifuge
tube containing 1 mL  of 50 mM EDTA (Sigma Chemical), pH
8.0,  mixed, and centrifuged at 13,000 × g for 15 min. The super-
natant  was  removed, and the pellet was  resuspended in 200 L
of 50 mM EDTA, pH 8.0, containing 40 L of lysing enzyme from
Trichoderma  harzianum (10 mg/mL) (Sigma Chemical), and then
incubated at 37 ◦C for 2 h. Subsequently, this mixture was  cen-
trifuged  at 13,000 × g for 10 min, and the pellet was  dissolved in
lysis  buffer containing 10 mM Tris–HCl, pH 8.0; 10 mM  EDTA,
pH  8.0; 0.5% sodium dodecyl sulfate; 0.01% N-laurilsarcosyl;
and 100 mg/mL  proteinase K. The mixture was vortex mixed
and  incubated at 56 ◦C for 2 h.
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DNA  puriﬁcation  and  PCR
DNA molecules of protoplasts or CSF samples were  extracted
by  QIAamp DNA Mini Kit (Qiagen) according to the manufac-
turer’s  instructions. CSF samples were  previously centrifuged
for  15 min  at 9000 × g. Packed cells were  washed twice in PBS
to  prevent the action of any Taq polymerase inhibitor. Whole
cells  were  incubated for 15 min  at 100 ◦C in 200 L of ultra-
pure  water containing four to ﬁve 1.5 mm glass beads. Next,
the  cells were  processed in a TissueLyser disruptor (Qiagen) for
two cycles of 3 min. After DNA extraction, the purity was  deter-
mined  by the ratio of O.D. at 260 and 280 nm in a NanoDrop
ND100 (Thermo Fisher Scientiﬁc, Waltham, MA,  US).
The  ampliﬁcations were  carried out with a kit purchased
from Promega (Go Taq Green Master Mix). The PCR mix
(12.5  L) consisted of 1 unit of Green GoTaq® DNA poly-
merase, 10 mM Tris–HCl, pH 8.5; 50 mM KCl; 1.5 mM MgCl2; and
200  mM of each dNTP. The reactions included the PCR mix,
10  L of each DNA template and 25 pmol of each primer to
a  ﬁnal volume of 25 L. The ampliﬁcations were performed
in  an automated thermal cycler and each run contained
one negative control (ultra-pure water) and one positive
(DNA  extracted from serotype A, VNI culture). After ther-
mal  cycles, PCR products were  electrophoresed in 2% agarose
gels  in TBE buffer and stained with ethidium bromide. The
size  of fragment was  based on a comparison with a 100-bp
ladder.
Primer  set  selection
The experiments were  carried out by using two primer sets.
The  ﬁrst set was  the CN4–CN5 (5′ATCACCTTCCCACTAACACA-
TT3′ and 5′GAAGGGCATGCCTGTTTGAGAG3′), which ampli-
ﬁed  a 136-bp sequence from a speciﬁc gene coding region
for  rDNA of C. neoformans as target.15 The ampliﬁca-
tions were  performed by one initial denaturation cycle
for  5 min  at 94 ◦C, 30 cycles of denaturation at 94 ◦C for
1  min, annealing at 55 ◦C for 1 min, and extension at 72 ◦C
for  1 min. The procedure was  completed by a ﬁnal cycle
extension for 10 min. The second was  a multiplex PCR.
The  CNa70S–CNa70A (5′ATTGCGTCCACCAAGGAGCTC3′ and
′ ′5 ATTGCGTCCATGTTACGTGGC3 ) ampliﬁed a 695-bp fragment
of  a region on C. neoformans chromosome 3 that includes the
coding  sequence of a putative aminotransferase gene. The
CNb49S–CNb-49A (5′ATTGCGTCCATCCAAGGTGTTGTTG3′ and
Table 1 – Evaluation of primer sets CN4–CN5 and CNa70S–CNa7
strains.
Standard strains 
CN4–
WM 148 (serotype A, VNI) Posit
WM 626 (serotype A, VNII) Posit
WM 628 (serotype AD VNIII) Posit
WM 629 (serotype D, VNIV) Posit
WM 179 (serotype B, VGI) Posit
WM 178 (serotype B, VGII) Posit
WM 175 (serotype B, VGIII) Posit
WM 779 (serotype C, VGIV) Posit 0 1 5;1  9(1):62–67
5′ATTGCGTCCATCCAACCGTTATC3′) ampliﬁed a 448-bp frag-
ment  of a region on C. gattii chromosome 2, which includes
the  coding sequence of a putative polymerase.14,19 The PCR
products  were  ampliﬁed by one initial denaturation cycle
for  5 min  at 94 ◦C, 35 cycles of denaturation at 94 ◦C for
45  s, annealing at 65 ◦C for 60 s, and extension at 72 ◦C for
60  s. The procedure was completed by a ﬁnal cycle exten-
sion  for 10 min. To control the course of extraction and
check  for PCR inhibitors, all samples were  assayed using the
primer  set 1–2 (5′ACCACCAACTTCATCCACGTTCACC3′ and
5′CTTCTGACACAACTGTGTTCACTAGC3′),20 which ampliﬁed a
140-bp fragment of the human -globulin gene. The reactions
using  the human primer set were  run simultaneously with the
same  temperature protocol for the CN4–CN5 primer set and in
the same PCR machine.
Data  analysis  and  quality  assurance
Separate rooms were used for: (1) DNA extraction; (2) PCR
mix  and primer preparation; (3) adding DNA from clinical
samples and positive control; and (4) post-PCR agarose gel
electrophoresis analysis. DNA clinical samples were  assayed
in  duplicate and, at least, twice. Clinical and laboratory (micro-
scopic  examination by India ink and latex agglutination)
diagnoses were  the gold-standard to establish sensitivity,
speciﬁcity, positive (PPV) and negative (NPV) predictive val-
ues,  which were calculated as: (i) sensitivity – ratio of true
positives/(true positives + false negatives) × 100; (ii) speciﬁcity
–  ratio of true negatives/(true negatives + false positives) × 100;
(iii)  PPV – ratio of true positives/(true positives + false
positives); and (iv) NPV – ratio of true negatives/(true nega-
tives  + false negatives).
Results
Two PCR primer sets to determine C. neoformans/C. gattii
species  complex in clinical samples were  evaluated since
they  ampliﬁed different genetic regions. Initially the primer
sets  were  evaluated for sensitivity using the standard strains.
CN4–CN5  primer set ampliﬁed the 136-bp product in all
standard  strains tested. The same DNA samples were also
tested  for CNa70S–CNa70A/CNb49S–CNb-49A multiplex. Four
standard  strains (serotypes A-VNI and VNII, serotype AD-
VNIII,  serotype D-VNIV) ampliﬁed the 695-bp fragment; and
0A/CNb49S–CNb-49A in PCR for Cryptococcus standard
Primer sets
CN5 CNa70S–CNa70A/CNb49S–CNb-49A
ive Positive
ive Positive
ive Positive
ive Positive
ive Negative
ive Positive
ive Negative
ive Positive
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Table 2 – Summary of the results using CN4–CN5 and CNa70S–CNa70A/CNb49S–CNb-49A primer sets in PCR using CSF
samples from AIDS patients.
Primer sets PPVa NPVb PCR results
Number  of samples (%)
Cryptococcal meningitis Other neurological diseases
Positivec Negative Total Positive Negatived Total
CN4–CN5 0.99 0.93 91 (94.8%) 5 96 1 68 (98.5%) 69
CNa70S–CNa70A 0.99 0.53 62 (64.6%) 34 96 1 68 (98.5%) 69
a Positive predictive value (PPV).
b Negative predictive value (NPV).
c Sensitivity (in percent) was calculated and determined considering the clinical and laboratory diagnosis described in Materials and methods
section.
d Speciﬁcity (in percent) was calculated and determined considering the c
section.
MM            1                2                3                 4
–136 bp
–448 bp
100–
–695 bp600–
Fig. 1 – Ampliﬁed PCR products of two different target
regions of Cryptococcus neoformans/C. gattii species
complex. CNa70S–CNa70A/CNb49S–CNb-49A multiplex
ampliﬁed a 695-bp product of C. neoformans (line 1) and
448-bp  of C. gattii (line 2). CN4–CN5 primer set, ampliﬁed a
136-bp  product (lines 3 and 4). The DNA fragments were
resolved  in 2% agarose gels stained with ethidium bromide.
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have  been few studies evaluating the efﬁcacy of such method-ane  MM,  100-bp ladder.
wo (serotype B-VGII and serotype C-VGIV) ampliﬁed the 448-
p  fragment. No ampliﬁed product was  shown in two standard
trains  (serotypes B-VGI and VGIII) (Table 1). These experi-
ents  were  conducted three times and, as an illustration,
ig.  1 shows the ampliﬁed PCR products of both primer sets
sed  in this study. Both did not amplify other yeasts such as
andida  albicans, C. parapsilosis, C. tropicalis, and C. glabrata.
The  good quality of all 165 DNA samples was  conﬁrmed
y the ampliﬁcation of 1–2 primer set that ampliﬁed a PCR
ragment  of human -globulin gene of 140-bp. Positive ampli-
cations  showed that no substance present in DNA samples
nhibited  the reactions.
Next,  the sensitivity and speciﬁcity of the CN4/CN5 and
he  CNa70S–CNa70A/CNb49S–CNb-49A multiplex were deter-
ined  in DNA samples extracted from CSF samples of both
roups  of patients. Table 2 shows the results of each group inlinical and laboratory diagnosis described in Materials and methods
detail. The analysis of the clinical samples from the CM/AIDS
group  revealed that 94.8% of these samples were  positive (91
out  of 96) using the CN4/CN5 primer set. The speciﬁcity of the
assay,  based on the analysis of all 69 negative samples from
CTL/AIDS  group was 98.5%.
According  to the multiplex CNa70S–CNa70A/CNb49S–CNb-
49A, no 448-bp product of C. gattii (CNb49S-CNb-49A) was
shown  in the clinical samples of either group. The 695-bp prod-
ucts  of C. neoformans were shown in only 64.6% (62 out of 96)
of  the CM/AIDS group. In CTL/AIDS, the speciﬁcity was also
98.5%.  Only one sample out of 69 had a false-positive result.
Although  the speciﬁcity was  good, the sensitivity was  very low
as well as the NPV (0.53).
Discussion
Despite the observed decline of cryptococcal meningitis in
AIDS  patients, its occurrence still represents a determinant
of  poor prognosis in HIV-infected patients.6 Additionally, this
fungal  infection in the central nervous system leads to severe
neurological complications. In this way,  its successful treat-
ment  depends on rapid and accurate identiﬁcation of the
causative  agent.16 Consequently, accurate and rapid diagnosis
is  critical. In recent years, great advances have been made in
developing laboratory techniques to diagnose infectious dis-
eases. Nevertheless, despite the well-established diagnosis of
cryptococcal  meningitis some aspects of the diagnosis remain
challenging  and there are still gaps that need to be addressed.
For  instance, a negative result from an in vitro culture might
be  due to the presence of nonviable or fastidious yeast in the
sample.  Thus, the use of PCR in CSF samples associated with
methods  already used at the laboratory could increase the
diagnostic  efﬁcacy.
Several  studies based on molecular methods have shown
that  C. neoformans isolates exhibit different degrees of genetic
heterogeneity among clinical and environmental isolates. The
primer  sets used in these Cryptococcus studies were  normally
used  for genotyping characterization.11,21–25 However, thereology  in molecular diagnosis. Here, we chose two previously
described primers’ set widely used for Cryptococcus genotyp-
ing.  Two primer sets were tested as they amplify different
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genetic regions. The CN4–CN5 primer set ampliﬁed a 136-bp
sequence  from a speciﬁc region of gene coding for rDNA as
target.15
The sensitivity, accuracy and speciﬁcity of a diagnostic
test depend also on optimal working conditions. In order
to  improve the PCR sensitivity, the CSF samples should be
processed  rapidly within 48 h of collection to prevent Taq poly-
merase  inhibition that could modify PCR results.26 In addition,
the  DNA extraction and PCR inhibitors may  be evaluated by a
primer set that ampliﬁed human PCR fragments. In this study,
positive  ampliﬁcations showed that no substance present in
DNA samples inhibited the reactions.
Firstly, the efﬁcacy of both primer sets was  analyzed using
Cryptococcus standard strains and then the clinical samples.
The  CN4–CN5 primer set was  highly sensitive since it ampli-
ﬁed  all Cryptococcus standard strains used in this study. These
data  were  further conﬁrmed using 96 clinical samples from
the  CM/AIDS group that revealed good sensitivity (94.8%) and
negative  predictive value of 0.93. Five cases of the CM/AIDS
group  were  false negatives. The PCR results could be due to
low  or non-uniform distribution of specimens from which the
DNA  was  extracted. Furthermore, the speciﬁcity was  also good
(98.5%)  with high positive predictive value (0.99). Only one
DNA  sample from CLR/AIDS had a false-positive result. Similar
results  have been reported previously.27
The use in molecular diagnosis of a multiplex primer set
could  be an excellent alternative, since in the same reac-
tion  it could be possible to detect the organism and, at
the  same time, genotype the infecting strain. For this pur-
pose,  the CNa70S–CNa70A/CNb49S–CNb-49A multiplex was
tested  in this study. According to previous studies, 695-bp
PCR  products were shown in C. neoformans strains and a 448-
bp  fragment of C. gattii.14,19 In this study, the PCR using the
(CNa70S–CNa70A/CNb49S–CNb-49A) multiplex was unable to
amplify two Cryptococcus standard strains (serotypes B-VGI and
VGIII).  In addition, no 448-bp product of C. gattii was  shown in
the clinical samples of either group. These data could suggest
that  the majority of the DNA samples from CM/AIDS had yeast
belonging  to C. neoformans. However, the 695-bp products of C.
neoformans  were  shown only in 64.6% of the CM/AIDS group
resulting  in low sensitivity with very low NPV (0.53). In the
CM/AIDS  group, 34 DNA samples had false-negative results.
Collectively these data suggest that although the multi-
plex  primer set could detect the organism and, at the same
time,  genotype the infecting strain, the sensitivity was  too
low.  On the other hand, the primer set CN4/CN5 was  highly
sensitive  for C. neoformans/C. gattii species complex determi-
nation  in CSF samples from patients with clinical suspicion of
cryptococcal  meningitis or the treatment control.
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